ELISA (enzyme-linked immuno sorbent assay) kit for assaying serologic preneoplastic markers of hepatitis B and hepatic cellular cancer and application of kit

Abstract

The invention relates to an ELISA (enzyme-linked immuno sorbent assay) kit for assaying serologic preneoplastic markers of hepatitis B and hepatic cellular cancer, and an application of the kit in quickly assaying hepatic precancerous lesion. According to the kit, a hepatic precancerous lesion antibody is assayed by a solid-phase immuno assay ELISA; abnormally expressed gene segments URG4, URG7, URG11, URG12, URG19 and URG2 are cloned by suppression cDNA (complementary deoxyribonucleic acid) subtractive hybridization in positive and negative HepG2 cell lines of an X gene; a hydrophyllic end sequence is selected, artificial polypeptide is subjected to solid-phase synthesis, and the ELISA kit for assaying serologic preneoplastic markers of hepatitis B and hepatic cellular cancer is prepared by using the artificial polypeptide as an envelope antigen. The kit can be used for effectively assaying hepatic precancerous lesion, is specific in method, easy to operate, low in price, safe and non-invasive, and can be used for assaying by a simple serological method.

Description

technical field The invention relates to an ELISA kit and its application, in particular to an ELISA kit for detecting precancerous lesion markers of hepatitis B and its application, and belongs to the field of medicine and health. Background technique Statistics in recent years show that the mortality rate of primary liver cancer in my country is 20.40 / 100,000, accounting for 45% of the world's liver cancer deaths. Although the primary prevention of liver cancer in my country has taken many measures including hepatitis B vaccine, the effect still needs to wait for decades. Therefore, the secondary prevention of early detection, early diagnosis and early treatment of liver cancer is particularly important. my country has carried out natural population census of alpha-fetoprotein (AFP) since 1971, but the effect is not satisfactory. In the 1980s, according to the results of epidemiological surveys, the high-risk groups of liver cancer were classified, and the general surve...

AI Technical Summary

Problems solved by technology

Since the positive rate of AFP detection for the diagnosis of liver cancer is only 60-80%, and the diagnosis of precancerous lesions cannot be performed, the research on precancerous blocking therapy cannot be carried out in clinical secondary prevention